---
layout: post
title: "Developing Drugs for Optical Imaging; Draft Guidance for Industry; Availability"
date: 2026-02-04 21:49:34 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-00213
original_published: 2025-01-08 00:00:00 +0000
significance: 8.00
---

# Developing Drugs for Optical Imaging; Draft Guidance for Industry; Availability

**Published:** February 04, 2026 21:49 UTC
**Source:** Federal Register
**Original Published:** January 08, 2025 00:00 UTC
**Document Number:** 2025-00213

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Developing Drugs for Optical Imaging." The purpose of this guidance is to provide recommendations to sponsors regarding clinical trial design features that support development and approval of optical imaging drugs that are used in conjunction with imaging devices and intended as intraoperative aids for the detection of pathology such as tumors or to enhance the conspicuity of normal anatomical structures.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/01/08/2025-00213/developing-drugs-for-optical-imaging-draft-guidance-for-industry-availability)
- API: https://www.federalregister.gov/api/v1/documents/2025-00213

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
